DataMEDS AI, Inc. (MEDS) Cash Flow Statement
DataMEDS AI, Inc. (MEDS) generated -$13.7M of operating cash flow over the twelve months to 2026-06-30, spent $923697 on capital expenditure and had free cash flow of -$14.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MEDSDataMEDS AI, Inc.Follow MEDS — free
—
Price chart with a free account
- Market cap
- 6.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 24 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -1.2 | -10.9 | -13.7 | |
| Capital expenditure | 0.4 | 0.9 | -0.9 | |
| Free cash flow | -1.6 | -11.7 | -14.7 | |
| Stock-based compensation | 1.1 | 54.8 | — |
USD millions · SEC XBRL
DataMEDS AI, Inc. — questions
- What is DataMEDS AI, Inc.'s operating cash flow?
- -$13.7M over the twelve months to 2026-06-30.
- How much does DataMEDS AI, Inc. spend on capital expenditure?
- $923697 over the twelve months to 2026-06-30.
- What is DataMEDS AI, Inc.'s free cash flow?
- -$14.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from DataMEDS AI, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.